Bmi-1 and Skin Cancer Prevention
Bmi-1 and Skin Cancer Prevention
批准号:
8081783
负责人:
Richard L. Eckert
金额:
$41.7万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2013-05-31
关键词:
AddressApoptosisAreaB-LymphocytesBindingBinding SitesBiological ModelsCDKN2A geneCell Cycle ProgressionCell DeathCell Differentiation processCell LineCell NucleusCell ProliferationCell SurvivalCell divisionCellsChemopreventionChemopreventive AgentChromatinComplexCyclin-Dependent KinasesCyclinsDeacetylationDevelopmentDietDrosophila genusEpidermisEpigallocatechin GallateEpigenetic ProcessEpithelialEventFamilyGene ExpressionGene Expression RegulationGene ProteinsGene SilencingGene TargetingGenesGoalsGreen teaHealthHematopoieticHistone DeacetylaseHistone H3HistonesHomologous GeneHumanIn VitroIncidenceLymphomagenesisLysineMalignant NeoplasmsMeasuresMediatingMediator of activation proteinMessenger RNAMethylationModelingMoloney Leukemia VirusMonitorMultiprotein ComplexesMusNeuronsPRC1 ProteinPhosphorylationPolycombPredispositionPreventivePropertyProteinsRNA chemical synthesisRecruitment ActivityRegulationResponse ElementsRoleSiteSkinSkin CancerSkin CarcinogenesisSkin NeoplasmsStem cellsSystemTestingTumor TissueUltraviolet B RadiationUltraviolet RaysVirus Integrationanti-cancer therapeuticbasecancer cellcancer chemopreventioncancer stem cellcancer therapycarcinogenesischromatin modificationdesignfunctional statusgallocatecholgenetic regulatory proteinin vivoin vivo Modelinnovationinterestkeratinocyteneoplastic cellnoveloverexpressionp19ARFpolyphenolpreventprotein complexprotein expressionresearch studyskin cancer preventiontherapeutic targettumorvector
中文摘要
描述(由申请人提供):
从癌症化学预防的角度来看,一个重要的策略是抑制细胞分裂和/或减少癌细胞的存活或使细胞对联合治疗更敏感。这一目标可以通过降低细胞存活蛋白的水平或活性来实现。多梳组(polycomb group,PcG)基因编码一组重要的细胞存活蛋白,其最初被发现用于增强干细胞存活。这些蛋白质通过全局表观遗传(染色质修饰)机制发挥作用,抑制基因表达并增强细胞存活。它们是表观遗传的关键控制者。因为它们促进细胞增殖和存活,并通过表观遗传机制起作用,PcG蛋白被认为具有作为抗癌治疗靶点的巨大潜力。尽管PcG基因在提高癌细胞存活率方面具有潜在的重要性,但饮食衍生的化学预防剂在调节其功能中的作用尚未得到解决。Bmi-1是一种多梳蛋白,在某些肿瘤类型中以高水平表达。我们的初步研究表明,Bmi-1在皮肤癌细胞和肿瘤中显著过表达,并且Bmi-1的靶向过表达增强了皮肤癌细胞的存活。此外,我们的研究表明,存在于绿色茶中的生物活性多酚,(-)-表没食子儿茶素-3-没食子酸酯(EGCG),降低Bmi-1水平,并且这种降低与皮肤癌细胞增殖和存活减少有关。这些发现表明,化学预防剂可能通过降低Bmi-1水平和活性来减少皮肤癌。化学预防剂可能通过干扰PcG基因依赖的表观遗传调节机制起作用的想法尚未被广泛考虑或研究。这项研究的主要目的是了解EGCG如何调节皮肤癌中Bmi-1的水平和活性。具体目标1中概述的研究旨在确定EGCG降低Bmi-1水平和活性的机制。具体目标2中概述的实验旨在了解Bmi-1水平的EGCG依赖性降低如何导致皮肤癌细胞存活率降低。具体目标3侧重于其他PcG基因产物的贡献,是Bmi-1多蛋白复合物的一部分,具体目标4研究Bmi-1的体内作用,使用表皮靶向Bmi-1过表达模型研究UVB依赖性皮肤癌。公共卫生相关性多梳(PcG)蛋白通过表观遗传(染色质修饰)机制发挥作用,以提高癌细胞的存活率。由于这种特性,PcG蛋白被认为具有作为抗癌治疗靶点的巨大潜力。绿色茶多酚是重要的饮食来源的癌症预防剂,可预防紫外线依赖性皮肤癌。我们的研究表明,绿色茶中的一种活性剂减少了皮肤癌细胞中的多梳基因表达,使它们更容易受到细胞死亡的影响。我们的目标是确定是否抑制Bmi-1 PcG蛋白的水平和功能是绿色茶多酚抑制紫外线依赖性皮肤癌发展的机制。这些研究被认为是创新的,因为化学预防剂对这种重要类型的表观遗传调控的影响以前没有被考虑过。
英文摘要
DESCRIPTION (provided by applicant):
From the perspective of cancer chemoprevention, an important strategy is to inhibit cell division and/or reduce the survival of cancer cells or to make the cells more sensitive to co-therapy. This goal can be achieved by reducing the level or activity of cell survival proteins. The polycomb group (PcG) genes encode an important group of cell survival proteins, which were originally discovered to enhance stem cell survival. These proteins act, via global epigenetic (chromatin modification) mechanisms, to suppress gene expression and enhance cell survival. They are key epigenetic controllers. Because they promote cell proliferation and survival and operate via an epigenetic mechanism, PcG proteins are regarded as having great potential as anti-cancer therapeutic targets. In spite of the potential importance of the PcG genes in enhancing cancer cell survival, the role of diet-derived chemopreventive agents in modulating their function has not been addressed. Bmi-1 is a polycomb protein that is expressed at high levels in some tumor types. Our preliminary studies show that Bmi-1 is markedly overexpressed in skin cancer cells and tumors, and that targeted overexpression of Bmi-1 enhances skin cancer cell survival. In addition, our studies show that the bioactive polyphenol present in green tea, (-)-epigallocatechin-3-gallate (EGCG), reduces Bmi-1 level and that this reduction is associated with reduced skin cancer cell proliferation and survival. These findings suggest that chemopreventive agents may act to reduce skin cancer by reducing Bmi-1 level and activity. The idea that chemopreventive agents may act by interfering with PcG gene- dependent epigenetic regulatory mechanisms has not been widely considered or studied. The major goal of this proposal is to understand how EGCG acts to regulate Bmi-1 level and activity in skin cancer. The studies outlined in Specific Aim 1 are designed to determine the mechanism(s) whereby EGCG reduces Bmi-1 level and activity. The experiments outlined in Specific Aim 2 are designed to understanding how the EGCG-dependent reduction in Bmi-1 level results in reduced skin cancer cell survival. Specific Aim 3 focuses on the contribution of other PcG gene products that are part of the Bmi-1 multiprotein complex, and Specific Aim 4 examines the in vivo role of Bmi-1 using an epidermis-targeted Bmi-1 overexpression model to study UVB-dependent skin carcinogenesis. PUBLIC HEALTH RELEVANCE The polycomb (PcG) proteins act via epigenetic (chromatin modification) mechanisms to enhance cancer cell survival. Because of this property, PcG proteins are regarded as having great potential as anti-cancer therapy targets. Green tea polyphenols are important diet-derived cancer preventive agents that prevent UV light-dependent skin cancer. Our studies show that an active agent in green tea reduces polycomb gene expression in skin cancer cells making them more susceptible to cell death. Our goal is to determine whether suppression of the level and function of the Bmi-1 PcG protein is a mechanism whereby green tea polyphenols inhibit the development of ultraviolet light-dependent skin cancer. These studies are regarded as innovative because the impact of chemopreventive agents on this important type of epigenetic regulation has not been previously considered for study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel sulforaphane cancer preventionmechanism
-
批准号:10335161
-
项目类别:
-
资助金额:$36.3万
-
财政年份:2018
-
负责人:Richard L. Eckert
-
依托单位:
A novel sulforaphane cancer preventionmechanism
-
批准号:10088420
-
项目类别:
-
资助金额:$44.31万
-
财政年份:2018
-
负责人:Richard L. Eckert
-
依托单位:
A novel sulforaphane cancer preventionmechanism
-
批准号:10524235
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2018
-
负责人:Richard L. Eckert
-
依托单位:
A novel sulforaphane cancer preventionmechanism
-
批准号:9754991
-
项目类别:
-
资助金额:$5.46万
-
财政年份:2018
-
负责人:Richard L. Eckert
-
依托单位:
Stem Cells and Skin Cancer Prevention and Angiogenesis
-
批准号:9248258
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2015
-
负责人:Richard L. Eckert
-
依托单位:
Stem Cells and Skin Cancer Prevention and Angiogenesis
-
批准号:9045587
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2015
-
负责人:Richard L. Eckert
-
依托单位:
Keratoderma- an Exploratory Study
-
批准号:8740156
-
项目类别:
-
资助金额:$19.57万
-
财政年份:2013
-
负责人:Richard L. Eckert
-
依托单位:
Keratoderma- an Exploratory Study
-
批准号:8588676
-
项目类别:
-
资助金额:$16.31万
-
财政年份:2013
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb genes and keratinocyte function
-
批准号:7847204
-
项目类别:
-
资助金额:$0.97万
-
财政年份:2009
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb genes and keratinocyte function
-
批准号:7900702
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:Richard L. Eckert
-
依托单位:
Bmi-1 and Skin Cancer Prevention
-
批准号:8284462
-
项目类别:
-
资助金额:$41.62万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Bmi-1 and Skin Cancer Prevention
-
批准号:7848939
-
项目类别:
-
资助金额:$43.08万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Bmi-1 and Skin Cancer Prevention
-
批准号:7666832
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb proteins and skin cancer prevention
-
批准号:9050641
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb genes and keratinocyte function
-
批准号:8044033
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb genes and keratinocyte function
-
批准号:8228180
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb proteins and skin cancer prevention
-
批准号:9257327
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Polycomb proteins and skin cancer prevention
-
批准号:8841325
-
项目类别:
-
资助金额:$42.59万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Bmi-1 and Skin Cancer Prevention
-
批准号:7527449
-
项目类别:
-
资助金额:$44.86万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
Bmi-1 and Skin Cancer Prevention
-
批准号:7812316
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2008
-
负责人:Richard L. Eckert
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: